TENAX THERAPEUTICS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 101 GLEN LENNOX DRIVE, CHAPEL HILL, NC, 27517
Mailing Address 101 GLEN LENNOX DRIVE, CHAPEL HILL, NC, 27517
Phone 919-855-2100
Fiscal Year End 1231
EIN 262593535
Financial Overview
FY2025
$7.16M
Total Liabilities
$97.07M
Stockholders' Equity
$97.60M
Cash & Equivalents
$-1.15
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | March 24, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K March 10, 2026
- Oral Levosimendan targets PH-pEF, an underserved cardiovascular condition with no FDA-approved therapies.
- Completed enrollment for pivotal LEVEL Phase 3 trial in Q4 2025, with top-line results expected in Q3 2026.
Insider Trading
BUY 4 insiders
15 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.